A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

计划入组 291 人 · 首次发布于 2019 年 12 月 26 日

ImmunoTEP for Patients With Medullary Thyroid Carcinoma.

计划入组 25 人 · 首次发布于 2012 年 11 月 21 日

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

计划入组 31 人 · 首次发布于 2013 年 9 月 19 日

RET inhibitor targeted degrader (solid tumors/NSCLC/sporadic medullary thyroid cancer)

Thyroid, porcine

RET kinase inhibitors (lung/thyroid/pancreatic cancer)

Rare Thyroid Therapeutics International AB

Sweden

Veracyte

United States

Aprea Therapeutics

United States

CStone Pharmaceuticals Receives NMPA Approval for Local Manufacturing of RET Inhibitor GAVRETO in China

FDA Grants Full Approval to Selpercatinib for RET-Mutant Medullary Thyroid Cancer

FDA Approves Lilly's Retevmo as First Targeted Therapy for RET-Positive Lung and Thyroid Cancers